Norman Wolmark
Norman Wolmark on the study’s frustrating but unequivocal results showing that bevacizumab did not extend disease-free survival in adjuvant therapy for early colon cancer at 3 years, even though there had been a benefit at 1 year. Also weighing in: Nicholas Petrelli.
LISTEN
[audio:https://www.audiomedica.com/podcasting/otbn/090914NormWomarkNiPetrelliPODCAST.mp3]
Blood test for free tumour DNA could guide breast cancer therapy 3 Apr, 2013 
Targeting Emerging Drugable Pathways in Breast Cancer—Clinical Potential Assessed 28 Mar, 2015 
ASCO Audio Journal of Oncology – June 4th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6; in the company of Julie Gralow 3 Jun, 2006 
Dog walking cuts breast cancer recurrence risk 29 Mar, 2013 
COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014